RNA Pull-Down Methods Compared
Team Dynamic Matrices | 1 July 2026
RNA pull-down, isolating specific RNA molecules or their binding partners from a complex mixture, underlies everything from RNA-protein interaction mapping to targeted RNA enrichment for sequencing. The main approaches differ mainly in what does the actual grabbing of the target.
Biotin-Streptavidin Pull-Down
Biotinylated probes complementary to the target RNA are captured via streptavidin-coated beads. This is a well-established, broadly trusted approach, but it's limited by probe design constraints and by bead-related off-target binding that can pull down unrelated material alongside the intended target.
Antibody-Based RNA Immunoprecipitation (RIP)
This captures RNA bound to a specific protein of interest, making it useful for studying RNA-protein complexes directly. Its main dependency is antibody quality, since results are only as reliable as the antibody's specificity for the target protein.
Aptamer-Based Pull-Down
RNA or DNA aptamers serve as the capture element instead of an antibody or biotin probe, offering high specificity once an aptamer has been developed. The tradeoff is that a new aptamer typically needs to be developed for each new target, which adds time before a new application can get started.
LASSO Capture
Newer methods sidestep some of these constraints by using programmable, sequence-specific DNA libraries instead of fixed probes or antibodies. This allows target specificity to be redesigned quickly through sequence changes, without requiring a new reagent development cycle each time the target changes.Choosing Between Them
If your target already has a well-validated antibody, RIP remains a strong, well-trodden choice. If you're working with a new or unusual target and need to move quickly, sequence-programmable capture methods reduce the lead time considerably compared to developing a new aptamer or sourcing a new antibody from scratch.
FAQs
This depends heavily on the specific target and probe or crosslinker design quality, but sequence-specific approaches generally outperform generalized bead-charge binding for closely related sequences.
Antibody-based methods depend on antibody availability, which can take weeks to months if a new antibody must be raised. Sequence-programmable methods can often be redesigned in days once the target sequence is known.